Literature DB >> 9166020

Relation between insulin-like growth factor-I, body mass index, and clinical status in cystic fibrosis.

A M Taylor1, A Bush, A Thomson, P J Oades, J L Marchant, C Bruce-Morgan, J Holly, L Ahmed, D B Dunger.   

Abstract

OBJECTIVES: Despite improved nutrition and intensive treatment, subjects with cystic fibrosis have difficulty in maintaining anabolism during intercurrent infections, which can result in reduced body mass index and impaired skeletal growth. Insulin-like growth factor-I (IGF-I) and its binding protein IGFBP3 are sensitive to changes in nutritional status. The aim of this study was to determine the relation between circulating concentrations of these peptides, body mass index, and clinical status in cystic fibrosis.
METHODS: Serum concentrations of IGF-I and IGFBP3 were measured in 197 subjects (108 males, 89 females; mean age 9.69 years, range 0.41-17.9 years) and these data were analysed with respect to body mass index, pubertal stage, and clinical status as assessed by Shwachman score and forced expiratory volume in one second (FEV1).
RESULTS: The mean height SD score of the children studied was -0.2 (SD 1.14) and the body mass index SD score -0.26 (1.4). The body mass index SD score declined with increasing age (r = -0.18) and paralleled changes in IGF-I concentrations, which also declined. The IGF-I SD score (calculated from control data) correlated with age (r = -0.53). The abnormalities were most obvious during late puberty, when IGF-I and IGFBP3 concentrations were significantly reduced compared with those in control subjects matched for pubertal stage. The IGF-I SD score correlated with height SD score (r = 0.14) and the decline in IGF-I concentrations with the fall in body mass index SD score (r = 0.42). IGF-I SD scores also correlated with the Shwachman score (r = 0.33) and FEV1 (r = 0.17).
CONCLUSIONS: The close relation between declining IGF-I and IGFBP3 concentrations and body mass index in patients with cystic fibrosis may simply reflect poor nutritional status and insulin hyposecretion. Nevertheless, IGF-I deficiency could also contribute towards the catabolism observed in these patients, and IGF-I SD scores correlated with other measures of clinical status such as the Shwachman score and FEV1.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9166020      PMCID: PMC1717156          DOI: 10.1136/adc.76.4.304

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  40 in total

1.  Long-term study of one hundred five patients with cystic fibrosis; studies made over a five- to fourteen-year period.

Authors:  H SHWACHMAN; L L KULCZYCKI
Journal:  AMA J Dis Child       Date:  1958-07

2.  Glucose tolerance in cystic fibrosis.

Authors:  S Lanng; B Thorsteinsson; G Erichsen; J Nerup; C Koch
Journal:  Arch Dis Child       Date:  1991-05       Impact factor: 3.791

3.  Efficacy of a nonrestricted fat diet in patients with cystic fibrosis.

Authors:  E Luder; M Kattan; J C Thornton; K M Koehler; R J Bonforte
Journal:  Am J Dis Child       Date:  1989-04

4.  Demonstration of normal plasma somatomedin concentrations in cystic fibrosis.

Authors:  R G Rosenfeld; C Landon; N Lewiston; R Nagashima; R L Hintz
Journal:  J Pediatr       Date:  1981-08       Impact factor: 4.406

5.  The effects of insulin and growth hormone on the release of somatomedin by the isolated rat liver.

Authors:  W H Daughaday; L S Phillips; M C Mueller
Journal:  Endocrinology       Date:  1976-05       Impact factor: 4.736

6.  Energy and nutrient intakes in cystic fibrosis.

Authors:  R M Buchdahl; C Fulleylove; J L Marchant; J O Warner; M J Brueton
Journal:  Arch Dis Child       Date:  1989-03       Impact factor: 3.791

7.  Cystic fibrosis in adolescents and adults.

Authors:  P Mitchell-Heggs; M Mearns; J C Batten
Journal:  Q J Med       Date:  1976-07

8.  Experimental kuru in the spider monkey. Histopathological and ultrastructural studies of the brain during early stages of incubation.

Authors:  E Beck; I J Bak; J F Christ; D C Gajdusek; C J Gibbs; R Hassler
Journal:  Brain       Date:  1975-12       Impact factor: 13.501

9.  Increased energy expenditure in young children with cystic fibrosis.

Authors:  R W Shepherd; T L Holt; L Vasques-Velasquez; W A Coward; A Prentice; A Lucas
Journal:  Lancet       Date:  1988-06-11       Impact factor: 79.321

10.  Relationship between insulin, insulin-like growth factor I, and dehydroepiandrosterone sulfate concentrations during childhood, puberty, and adult life.

Authors:  C P Smith; D B Dunger; A J Williams; A M Taylor; L A Perry; E A Gale; M A Preece; M O Savage
Journal:  J Clin Endocrinol Metab       Date:  1989-05       Impact factor: 5.958

View more
  12 in total

Review 1.  Growth and growth charts in cystic fibrosis.

Authors:  Leena Patel; Moira Dixon; T J David
Journal:  J R Soc Med       Date:  2003       Impact factor: 5.344

2.  Pigs and humans with cystic fibrosis have reduced insulin-like growth factor 1 (IGF1) levels at birth.

Authors:  Mark P Rogan; Leah R Reznikov; Alejandro A Pezzulo; Nicholas D Gansemer; Melissa Samuel; Randall S Prather; Joseph Zabner; Douglas C Fredericks; Paul B McCray; Michael J Welsh; David A Stoltz
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-08       Impact factor: 11.205

Review 3.  Appetite stimulants for people with cystic fibrosis.

Authors:  Diane McTavish; Judith Thornton
Journal:  Cochrane Database Syst Rev       Date:  2022-09-23

4.  Serum insulin-like growth factor-1 (IGF-1) during CF pulmonary exacerbation: trends and biomarker correlations.

Authors:  A H Gifford; A B Nymon; A Ashare
Journal:  Pediatr Pulmonol       Date:  2013-06-18

Review 5.  Growth hormone and exercise tolerance in patients with cystic fibrosis.

Authors:  Matthias Hütler; Ralph Beneke
Journal:  Sports Med       Date:  2004       Impact factor: 11.136

Review 6.  Recombinant growth hormone therapy for cystic fibrosis in children and young adults.

Authors:  Vidhu Thaker; Alexandra L Haagensen; Ben Carter; Zbys Fedorowicz; Brian W Houston
Journal:  Cochrane Database Syst Rev       Date:  2013-06-05

7.  Insulin-like growth factor I correlates with lean body mass in cystic fibrosis patients.

Authors:  I Sermet-Gaudelus; J C Souberbielle; I Azhar; J C Ruiz; P Magnine; V Colomb; C Le Bihan; D Folio; G Lenoir
Journal:  Arch Dis Child       Date:  2003-11       Impact factor: 3.791

Review 8.  Recombinant growth hormone therapy for cystic fibrosis in children and young adults.

Authors:  Vidhu Thaker; Ben Carter; Melissa Putman
Journal:  Cochrane Database Syst Rev       Date:  2021-08-23

9.  Recombinant growth hormone therapy for cystic fibrosis in children and young adults.

Authors:  Vidhu Thaker; Ben Carter; Melissa Putman
Journal:  Cochrane Database Syst Rev       Date:  2018-12-17

10.  Insulin-like growth factor 1 (IGF-1) enhances the protein expression of CFTR.

Authors:  Ha Won Lee; Jie Cheng; Olga Kovbasnjuk; Mark Donowitz; William B Guggino
Journal:  PLoS One       Date:  2013-03-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.